Search

The article presents a case study of a 79-year-old female patient with delirium and auditory and visual hallucinations for several weeks. Topics include patient presenting to a hospital outside the institution with nausea and vomiting diagnosed as having acute kidney injury (AKI); and having a history of hypertension, hyperlipidemia, chronic diastolic congestive heart failure, peripheral vascular disease, meningioma.

Aims: To determine the roles of the presence of malignancy, tumour proliferation fraction, vascular compromise and therapeutic and diagnostic manipulations in lymph node infarction (LNI). Methods and results: Thirty-five cases of LNI were identified over a 20-year period. Of the 35 patients, 31 (89%) had an underlying malignancy: 27 of the 31 (87%) were haematologic malignancies, the rest being metastatic carcinoma (two), melanoma, and seminoma. Of the four patients without evidence of malignancy, two were diagnosed with viral infection, one had LNI adjacent to a thrombosed pancreas graft, and one was lost to follow-up. Ki67 immunostaining in viable tumour demonstrated a range (5-60%) of proliferation fractions. A history of fine needle aspiration alone was present in seven of the 35 patients (20%), a history of chemotherapy alone in 11 (31%), and a history of both in two (5.7%). Factor VIII immunostaining highlighted thrombosed and recanalized vessels next to the infarction. Conclusions: Infarction of lymph nodes is associated with previous, concurrent or subsequent diagnosis of malignancy in the vast majority of cases. Chemotherapy or previous fine needle aspiration can precipitate infarction in some cases, but infarction may occur without such intervention, possibly because of an underlying subacute or chronic vascular compromise produced by vascular thrombosis. [ABSTRACT FROM AUTHOR]

Histone H4 acetylation was examined by immunohistochemistry in patients with acute lymphocytic leukaemia (ALL) in first relapse. Univariate and multivariate models identified correlates of complete remission (CR) and overall survival (OS). No variables were associated with achievement of CR. In multivariate analysis, weak histone H4 acetylation [Hazard Ratio (HR) 2·20, 95% confidence interval (CI) 0·93-5·23, P = 0·07], shorter interval from diagnosis to relapse (<9 vs. 9-24 vs. >24 months) (HR 1·82, 95% CI 1·20-2·75, P = 0·005), and central nervous system involvement (HR 3·43, 95% CI 1·31-8·99, P = 0·01) were independent poor prognostic factors for OS. These data provide a rationale for the use of histone deacetylase inhibitors in the treatment of relapsed ALL. [ABSTRACT FROM AUTHOR]

The article presents a study that reviews survival of secondary acute myeloid leukemia (SAML) patients receiving aggressive induction chemotherapy. The study shows that the overall survival was 13.6 months and median event-free survival was eight months. It reveals that eight patients passed away shortly after receiving induction therapy due to side effects or the disease. It indicates that the median disease-free survival for patients attaining morphologic complete remission was nine months.